ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

October 18, 2021
Preprint
Open Access

Treatment with IFB-088 improves neuropathy in CMT1A and CMT1B mice

BioRxiv : the Preprint Server for Biology
Y. BaiMaurizio D'Antonio
October 16, 2021
Review

Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases.

Molecular Neurobiology
Della Grace Thomas ParambiBijo Mathew
October 15, 2021
Review

Antioxidant properties of flavonoid metal complexes and their potential inclusion in the development of novel strategies for the treatment against neurodegenerative diseases.

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Esteban Rodríguez-Arce, Marianela Saldías
October 15, 2021

The Sigma-1 receptor is an ER-localized type II membrane protein.

The Journal of Biological Chemistry
Neeraj SharmaGerardo Z Lederkremer
October 13, 2021

Pain, disease severity and associations with individual quality of life in patients with motor neuron diseases.

BMC Palliative Care
Ylva ÅkerblomPernilla Åsenlöf
October 13, 2021

Therapeutic acute intermittent hypoxia: A translational roadmap for spinal cord injury and neuromuscular disease.

Experimental Neurology
Alicia K VoseGordon S Mitchell
October 13, 2021

Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function.

Journal of Medicinal Chemistry
Scott E CollibeeBradley P Morgan
October 13, 2021
Open Access

Bisperoxovanadium promotes motor neuron survival and neuromuscular innervation in amyotrophic lateral sclerosis.

Molecular Brain
Junmei WangChandler L Walker
October 13, 2021
Review

Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases.

Journal of Biomedical Science
Ching-Pang ChangYijuang Chern
October 11, 2021
Review
Open Access

Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy.

Frontiers in Neuroscience
Luca MuzioGianvito Martino
October 9, 2021
Review

Acute intermittent hypoxia and respiratory muscle recruitment in people with amyotrophic lateral sclerosis: A preliminary study.

Experimental Neurology
Elaheh SajjadiBarbara K Smith
October 7, 2021

A Novel Supplement Attenuates Oxidative Stress-Induced TDP-43-Related Pathogenesis in TDP-43-Expressed Cells.

Evidence-based Complementary and Alternative Medicine : ECAM
Eun Jin Yang
September 30, 2021

Correlations between measures of ALS respiratory function: is there an alternative to FVC?

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
Deirdre MurrayOrla Hardiman
September 29, 2021

Targeting autotaxin impacts disease advance in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.

Brain Pathology
Ángela Gento-CaroBernardo Moreno-López
September 29, 2021
Review
Open Access

Current Concepts on Genetic Aspects of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis.

International Journal of Molecular Sciences
Milena JankovicDejan Nikolic
September 29, 2021
Open Access

A Computational Workflow for the Identification of Novel Fragments Acting as Inhibitors of the Activity of Protein Kinase CK1δ.

International Journal of Molecular Sciences
Giovanni BolcatoStefano Moro

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

© 2021 Meta ULC. All rights reserved
/feed-previews/als-therapies/70cf9704-ab72-4a54-b1b1-b2e7d895a2cc